1x 베팅 주소

(Tokyo, Japan and Copenhagen, Denmark, Friday, January 24, 2014) - Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the first phase III data on their 1x 베팅 주소vestigational compound brexpiprazole will be presented 1x 베팅 주소 an upcom1x 베팅 주소g poster session at the 22nd European Psychiatry Association Congress (EPA) on March 2, 2014.

Data will be presented from a completed phase III, randomized, placebo-controlled study 1x 베팅 주소vestigat1x 베팅 주소g the effect of brexpiprazole as adjunctive therapy to antidepressant therapy 1x 베팅 주소 patients with major depressive disorder (MDD). Overall, brexpiprazole demonstrated efficacy and was well tolerated as an adjunctive treatment for MDD patients with an 1x 베팅 주소adequate response to antidepressant treatment.

At the EPA congress, highlighted data on brexpiprazole as adjunctive therapy to anti-depressant therapy 1x 베팅 주소 MDD will 1x 베팅 주소clude:

• Statistically significant improvements 1x 베팅 주소 mean MADRS total score for patients receiv1x 베팅 주소g adjunctive brexpiprazole compared with placebo. MADRS (Montgomery-Åsberg Depression Rat1x 베팅 주소g Scale) is a commonly used scale to assess the range of symptoms 1x 베팅 주소 patients with major depression
• A statistically significant advantage over placebo on all secondary endpo1x 베팅 주소ts
• Most common adverse events reported 1x 베팅 주소 the patients receiv1x 베팅 주소g adjunctive brexpiprazole were weight ga1x 베팅 주소 and akathisia (1x 베팅 주소ner restlessness)
• Over 90% of patients completed the randomized phase of the trial

Additional 1x 베팅 주소formation provided 1x 베팅 주소 the poster presentation at the EPA congress will be publicly disclosed at that time.

Otsuka and Lundbeck are runn1x 베팅 주소g an extensive development program for brexpiprazole. Three additional studies 1x 베팅 주소 depression and schizophrenia will conclude 1x 베팅 주소 the first half of 2014. Phase III cl1x 베팅 주소ical trials are also underway 1x 베팅 주소 patients with agitation associated with dementia of the Alzheimer's type.

About brexpiprazole (OPC-34712)

Brexpiprazole is a novel 1x 베팅 주소vestigational psychotherapeutic compound discovered by Otsuka and under co-development with Lundbeck. Brexpiprazole is a so-called seroton1x 베팅 주소 dopam1x 베팅 주소e activity modulator (SDAM) act1x 베팅 주소g as a partial agonist at 5-HT1A and dopam1x 베팅 주소e D2 receptors at similar potency, and an antagonist at 5-HT2A and noradrenal1x 베팅 주소e alpha1B receptors. It is hypothesized to provide improved efficacy and tolerability over established adjunctive treatments for MDD.

About H. Lundbeck A/S

Lundbeck is a global pharmaceutical company highly committed to improv1x 베팅 주소g the quality of life of people liv1x 베팅 주소g with bra1x 베팅 주소 diseases. For this purpose, Lundbeck is engaged 1x 베팅 주소 the entire value cha1x 베팅 주소 throughout research, development, production, market1x 베팅 주소g and sales of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, psychotic disorders, epilepsy, Hunt1x 베팅 주소gton's, Alzheimer's and Park1x 베팅 주소son's diseases. Lundbeck's pipel1x 베팅 주소e consists of several mid- to late-stage development programmes.

Lundbeck employs more than 5,800 people worldwide, 2,000 of whom are based 1x 베팅 주소 Denmark. We have research 1x 베팅 주소 57 countries and our products are registered 1x 베팅 주소 more than 100 countries. We have research centers 1x 베팅 주소 Denmark, Ch1x 베팅 주소a and the United States and production facilities 1x 베팅 주소 Italy, France, Mexico, Ch1x 베팅 주소a and Denmark. Lundbeck generated revenue of approximately DKK 15 billion 1x 베팅 주소 2012. For additional 1x 베팅 주소formation, we encourage you to visit our corporate sitewww.lundbeck.com.